Genovate Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of December 2025: 20.77%

Genovate Biotechnology Co Ltd (4130) has an Asset Resilience Ratio of 20.77% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Genovate Biotechnology Co Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

NT$312.92 Million
≈ $9.86 Million USD Cash + Short-term Investments

Total Assets

NT$1.51 Billion
≈ $47.46 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Genovate Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Genovate Biotechnology Co Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Genovate Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Genovate Biotechnology Co Ltd (4130) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$312.92 Million 20.77%
Total Liquid Assets NT$312.92 Million 20.77%

Asset Resilience Insights

  • Good Liquidity Position: Genovate Biotechnology Co Ltd maintains a healthy 20.77% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Genovate Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Genovate Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ALK-Abelló A/S
CO:ALK-B
Biotechnology 0.98%
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Biotechnology 6.89%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for Genovate Biotechnology Co Ltd (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Genovate Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 20.77% NT$312.92 Million
≈ $9.86 Million
NT$1.51 Billion
≈ $47.46 Million
+1.92pp
2024-12-31 18.86% NT$299.87 Million
≈ $9.45 Million
NT$1.59 Billion
≈ $50.10 Million
-3.59pp
2023-12-31 22.45% NT$359.27 Million
≈ $11.32 Million
NT$1.60 Billion
≈ $50.42 Million
+3.09pp
2022-12-31 19.36% NT$302.88 Million
≈ $9.54 Million
NT$1.56 Billion
≈ $49.29 Million
+6.76pp
2021-12-31 12.60% NT$190.98 Million
≈ $6.02 Million
NT$1.52 Billion
≈ $47.75 Million
0.00pp
2020-12-31 12.60% NT$197.98 Million
≈ $6.24 Million
NT$1.57 Billion
≈ $49.49 Million
-3.74pp
2019-12-31 16.35% NT$257.10 Million
≈ $8.10 Million
NT$1.57 Billion
≈ $49.56 Million
+1.82pp
2018-12-31 14.52% NT$252.10 Million
≈ $7.94 Million
NT$1.74 Billion
≈ $54.69 Million
-0.02pp
2017-12-31 14.54% NT$296.92 Million
≈ $9.35 Million
NT$2.04 Billion
≈ $64.33 Million
-3.82pp
2016-12-31 18.37% NT$486.00 Million
≈ $15.31 Million
NT$2.65 Billion
≈ $83.37 Million
-3.02pp
2015-12-31 21.39% NT$538.40 Million
≈ $16.96 Million
NT$2.52 Billion
≈ $79.31 Million
--
pp = percentage points

About Genovate Biotechnology Co Ltd

TWO:4130 Taiwan Biotechnology
Market Cap
$115.03 Million
NT$3.65 Billion TWD
Market Cap Rank
#18750 Global
#1016 in Taiwan
Share Price
NT$26.70
Change (1 day)
-0.37%
52-Week Range
NT$18.75 - NT$36.80
All Time High
NT$56.99
About

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more